We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMER icon
126
Omeros
OMER
$816M
$572K 0.24%
40,068
+132
+0.3% +$1.61K
IRWD icon
127
Ironwood Pharmaceuticals
IRWD
$626M
$568K 0.24%
49,908
-14,038
-22% -$154K
TBPH icon
128
Theravance Biopharma
TBPH
$875M
$568K 0.24%
31,966
+8,818
+38% +$158K
PTCT icon
129
PTC Therapeutics
PTCT
$6.25B
$563K 0.23%
9,220
-2,643
-22% -$156K
JQC icon
130
Nuveen Credit Strategies Income Fund
JQC
$702M
$560K 0.23%
88,528
-780
-0.9% -$4.77K
AMRS
131
DELISTED
Amyris Inc.
AMRS
$560K 0.23%
90,634
+11,400
+14% +$36.4K
VIE
132
DELISTED
Viela Bio, Inc. Common Stock
VIE
$556K 0.23%
15,471
+8,887
+135% +$311K
RARE icon
133
Ultragenyx Pharmaceutical
RARE
$2.56B
$550K 0.23%
3,972
-4,615
-54% -$547K
PRVL
134
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$544K 0.23%
23,601
+3,828
+19% +$48.5K
CGBD icon
135
Carlyle Secured Lending
CGBD
$719M
$541K 0.22%
52,775
-31,819
-38% -$315K
HRMY icon
136
Harmony Biosciences
HRMY
$2.07B
$539K 0.22%
+14,899
New +$601K
ESPR
137
DELISTED
Esperion Therapeutics
ESPR
$535K 0.22%
20,576
+7,134
+53% +$214K
INSM icon
138
Insmed
INSM
$22.6B
$508K 0.21%
15,252
-6,244
-29% -$228K
EPZM
139
DELISTED
Epizyme, Inc
EPZM
$506K 0.21%
46,638
+12,952
+38% +$160K
PSEC icon
140
Prospect Capital
PSEC
$1.12B
$498K 0.21%
92,036
-13,572
-13% -$71.5K
CSWC icon
141
Capital Southwest
CSWC
$1.48B
$483K 0.2%
27,187
+12,388
+84% +$195K
ICPT
142
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$466K 0.19%
18,849
+11,075
+142% +$367K
BNTX icon
143
BioNTech
BNTX
$23.4B
$458K 0.19%
5,621
-742
-12% -$72.8K
TCPC icon
144
BlackRock TCP Capital
TCPC
$274M
$443K 0.18%
39,441
-18,089
-31% -$196K
HGEN
145
DELISTED
HUMANIGEN, INC.
HGEN
$432K 0.18%
+24,667
New +$295K
ARVN icon
146
Arvinas
ARVN
$529M
$429K 0.18%
5,053
-4,773
-49% -$165K
NMFC icon
147
New Mountain Finance
NMFC
$668M
$428K 0.18%
37,694
-14,911
-28% -$160K
FDUS icon
148
Fidus Investment
FDUS
$766M
$425K 0.18%
32,420
+11,336
+54% +$135K
PFLT icon
149
PennantPark Floating Rate Capital
PFLT
$705M
$423K 0.18%
40,207
-22,553
-36% -$213K
BGX
150
Blackstone Long-Short Credit Income Fund
BGX
$136M
$422K 0.18%
31,430
-4,007
-11% -$52.6K
4 5
6
7 8

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.